SHEILA CAI: Open Payments
NPI 1780625012 · SAN MARCOS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,181 in 76 payments from 12 companies in 2025. Trend: 2023 $960 · 2024 $1,919 · 2025 $2,181
Food & beverage: $2,069Education: $111
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $531 |
| Otsuka America Pharmaceutical, Inc. | 12 | $388 |
| Supernus Pharmaceuticals, Inc. | 8 | $227 |
| Vanda Pharmaceuticals Inc. | 7 | $196 |
| Lundbeck LLC | 9 | $167 |
| Teva Pharmaceuticals USA, Inc. | 5 | $153 |
| E.R. Squibb & Sons, L.L.C. | 3 | $143 |
| Corcept Therapeutics | 1 | $104 |
| Alkermes, Inc. | 5 | $104 |
| Neurocrine BioSciences, Inc. | 4 | $93 |
Products named: CAPLYTA, ABILIFY MAINTENA, Qelbree, REXULTI, HETLIOZ, COBENFY, ABILIFY ASIMTUFII, Korlym.
Industry payments across CA — which companies pay providers there.
